Sign up USA
Proactive Investors - Run By Investors For Investors

Oragenics is well funded to resume Phase 2 clinical trial for oral mucositis

Oragenics Inc (NYSEAMERICAN:OGEN) CEO Alan Joslyn updates Proactive Investors on the Florida based biotech's advancements in the last six months.

Joslyn says the company's lead candidate AG013, which treats oral mucositis, resumed its Phase 2 clinical trial of AG013, following a positive review by an independent Data Safety Monitoring Board, with data expected in the middle of 2019. Joslyn says the trial will soon be expanded into 50 centers in the US and into Europe to complete patient enrollment.

Joslyn says the company recently raised $13.8mln to carry the biotech's programs through clinical trials. He says from this point forward most of the work within the company is operational.

 
View full OGEN profile View Profile

Oragenics Inc Timeline

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use